advisorsecurities master

INTSIntensity Therapeutics, Inc. Common stock

CSNasdaq (XNAS)·USD

Identity

Security key
17134
Ticker
INTS
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2023-06-30
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
INTS

Detail

Enriched 2026-08-14 20:47

Market cap
$11,243,731.2
Shares outstanding (class)
2,702,820
Shares outstanding (weighted)
2,702,820
SIC
2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
7
Location
SHELTON, CT
Description

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data